Vaxcyte, Inc. $PCVX Shares Acquired by Polar Capital Holdings Plc

Polar Capital Holdings Plc boosted its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 302.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,672,783 shares of the company’s stock after buying an additional 1,257,253 shares during the period. Polar Capital Holdings Plc owned 1.28% of Vaxcyte worth $77,182,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC boosted its holdings in shares of Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in Vaxcyte by 1,463.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after purchasing an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Vaxcyte by 33.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after purchasing an additional 184 shares during the period. Allworth Financial LP boosted its stake in Vaxcyte by 148.9% during the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after purchasing an additional 731 shares during the period. Finally, Aster Capital Management DIFC Ltd bought a new position in Vaxcyte in the 3rd quarter worth about $45,000. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Trading Down 0.5%

Vaxcyte stock opened at $49.31 on Wednesday. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00. The stock has a market cap of $7.12 billion, a price-to-earnings ratio of -7.17 and a beta of 1.24. The company’s 50-day moving average price is $53.93 and its two-hundred day moving average price is $52.68.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the prior year, the business earned ($1.04) EPS. Research analysts expect that Vaxcyte, Inc. will post -7.56 earnings per share for the current fiscal year.

Insider Activity at Vaxcyte

In other news, CAO Elvia Cowan sold 3,000 shares of Vaxcyte stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $60.00, for a total transaction of $180,000.00. Following the transaction, the chief accounting officer directly owned 28,975 shares in the company, valued at approximately $1,738,500. This trade represents a 9.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $49.52, for a total value of $111,420.00. Following the completion of the sale, the chief operating officer directly owned 158,494 shares in the company, valued at $7,848,622.88. This represents a 1.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 7,500 shares of company stock worth $419,288. 3.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. BTIG Research increased their price objective on Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Wall Street Zen cut Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.